Using a labyrinth device that exploits the physical characteristics of CTCs and a combination of HCC-specific antibodies against GPC3, glutamine synthetase, and HepPar-1 for ICC analysis, Wan et al. detected CTCs in 88.1% of patients with HCC and correlated the positivity rate of CTCs with the tumor stage [73]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.